Compare iShares MBS ETF (MBB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MBS ETF trades at $92.85, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while iShares MBS ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| MBB | REGN | |
|---|---|---|
52-Week High | $96.91 | $812.27 |
52-Week Low | $92.72 | $555.51 |
Market Cap | — | $83.19B |
Sector | — | Health |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB stock trades at $93.27, up 0.28% on the day, with technical indicators showing a bearish trend from moving averages and neutral oscillators. Recent corporate actions include dividend declarations for 2026, with payments of $0.33 and $0.34 per share. The stock lacks key valuation ratios in the provided data, suggesting limited fundamental visibility for analysis.
The outlook for MBB is cautious due to bearish technical signals and incomplete financial data. Risks include market volatility and reliance on future dividend payments for investor returns. Investment opportunity hinges on improved fundamental disclosures and positive earnings momentum, which are currently unverified.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
